Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have been given an average recommendation of “Hold” by the nine research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $114.25.
ENTA has been the subject of several recent analyst reports. BidaskClub raised shares of Zions Bancorporation NA from a “sell” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research downgraded shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. Berenberg Bank set a €126.00 ($146.51) target price on shares of Nemetschek and gave the company a “neutral” rating in a research note on Tuesday, April 23rd. Finally, Wolfe Research initiated coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an “outperform” rating and a $117.00 target price for the company.
NASDAQ:ENTA traded down $0.42 during trading hours on Wednesday, hitting $76.56. The stock had a trading volume of 19,346 shares, compared to its average volume of 157,932. Enanta Pharmaceuticals has a one year low of $64.08 and a one year high of $106.80. The stock has a market cap of $1.51 billion, a P/E ratio of 22.00 and a beta of 1.03. The firm has a 50 day moving average price of $84.86.
Several institutional investors have recently added to or reduced their stakes in the company. Aperio Group LLC boosted its holdings in shares of Enanta Pharmaceuticals by 5.3% in the second quarter. Aperio Group LLC now owns 8,036 shares of the biotechnology company’s stock valued at $678,000 after buying an additional 406 shares during the period. Dupont Capital Management Corp boosted its holdings in shares of Enanta Pharmaceuticals by 9.5% in the second quarter. Dupont Capital Management Corp now owns 13,477 shares of the biotechnology company’s stock valued at $1,137,000 after buying an additional 1,174 shares during the period. First Trust Advisors LP boosted its holdings in shares of Enanta Pharmaceuticals by 65.0% in the second quarter. First Trust Advisors LP now owns 41,635 shares of the biotechnology company’s stock valued at $3,513,000 after buying an additional 16,401 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 1,189.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 69,102 shares of the biotechnology company’s stock valued at $5,831,000 after buying an additional 63,742 shares during the period. Finally, Granite Point Capital Management L.P. acquired a new position in shares of Enanta Pharmaceuticals in the second quarter valued at approximately $422,000. Institutional investors own 89.52% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Story: The components of the Stochastic Momentum Index
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.